Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg ...

In previous treat-to-target trials, adjustments to the dose of basal insulin have been made at least weekly, according to ...

One of the more difficult decisions for patients with poorly controlled type 2 diabetes, as well as for their clinicians, is ...

A 34-year-old man was admitted to the hospital because of left ear pain with hearing loss and facial droop on the left side. Computed tomography showed a nasopharyngeal mass. A diagnosis was made.

Cancer of unknown primary site is an ever-evolving disease entity and one of the most challenging diagnoses to manage in oncology. 1-3 The term “cancer of unknown primary site” encompasses a ...

A total of 415 patients were assigned to cemiplimab (209) or placebo (206). The median follow-up was 24 months. Cemiplimab was superior to placebo with respect to disease-free survival (24 vs. 65 ...

The switch from fetal γ-globin to adult β-globin is controlled by BCL11A. Genetic manipulation of BCL11A improves disease outcomes by turning γ-globin expression back on to compensate for ...

We evaluated whether regional nodal irradiation improves outcomes in patients with biopsy-proven, node-positive breast cancer who reach ypN0 status after neoadjuvant chemotherapy.

Maternal infections underlie several adverse birth outcomes. Whether trimethoprim–sulfamethoxazole prophylaxis during pregnancy will improve birth outcomes is unknown.In a double-blind ...

Among 485 patients who were MRD-negative at 10 −5 sensitivity after induction, a premaintenance MRD-negative status at 10 −6 sensitivity occurred in 86% in the ASCT group and in 84% in the Isa ...

The Covid-19 vaccine resource center includes a collection of articles, FAQs, and related content to help educate and empower clinicians and their practice.

Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer.